Back to Agenda
[Student Session] Global Development and Benefit and Risk Assessment of Drugs
Session Chair(s)
Anna Ishii
Student, Tokyo University of Science, Japan
Misa Mori
Integrated Engagement Services Division, IQVIA Servicies Japan K.K., Japan
Mio Saito, MPHARM
PAREXEL Clinical Research Services, PAREXEL International Inc., Japan
Mana Shibasaki
Clinical Development Dept., JAPAN TOBACCO INC., Japan
The Student Session is the open place for students who are interested in the development of pharmaceutical products to get together and learn about drug development through interaction with industry, regulatory, and academia professionals. It provides a great opportunity for students to develop their knowledge and skill to be future leaders. This session will deliver two lectures, one about global clinical development, and the other is on how to evaluate benefit-risk of pharmaceutical products. After these lectures, we will gain more understanding about these themes by group discussion and feedback. Another aim of this session is to provide students with business skills, such as communication skills, required for global leaders.
Speaker(s)
Kohei Wada, MS
Corporate Officer, Vice President, Japan Development Head, R&D Division, Daiichi Sankyo Co., Ltd., Japan
To Future Leaders Who Will Drive Global Drug Development from Japan
Osamu Komiyama
Senior Manager, Statistical Research & Data Science, Pfizer R&D Japan G.K., Japan
Benefit-Risk Assessment of Drugs
Akihiro Nakajima
Pharmaceutical Development Administration Department, Teijin Pharma Limited, Japan
Hands-on Session
Have an account?